Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Mersana Therapeutics Inc's Business Segments
Mersana Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 11
Regions Reported
-
Revenue Share by Reportable Segment - Q3 FY2025
- Reportable100%
Revenue by Reportable Segment - Q3 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 11 | 100% |
Description of Mersana Therapeutics Inc
Mersana Therapeutics Inc. is a biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs) for the treatment of various types of cancer. The company was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Mersana's primary aim is to revolutionize cancer treatment by combining the specificity of antibodies with the potency of small molecules. By targeting cancer cells with precise antibodies and delivering potent drugs directly to them, Mersana's ADCs have the potential to enhance the efficacy of cancer therapies while minimizing the side effects associated with traditional treatments.
The company's proprietary platform, called Fleximer, forms the foundation of their ADC technology. Fleximer is a biodegradable polymer that can be customized to carry both small molecule drugs and antibodies. This platform enables the development of ADCs with enhanced stability, increased drug loading capacity, prolonged circulation time, and controlled drug release.
Mersana's lead product candidate, XMT-1536, is an ADC targeting NaPi2b, a protein highly expressed in multiple tumor types, including ovarian, lung, and colorectal cancers. XMT-1536 utilizes Fleximer to deliver a highly potent DNA crosslinking agent directly to cancer cells, leading to DNA damage and cell death. The company has completed Phase 1 clinical trials for XMT-1536 and is currently evaluating its safety and efficacy in various Phase 2 trials.
In addition to XMT-1536, Mersana has a pipeline of other ADC candidates at different stages of development. This includes XMT-1592, a CD205-targeted ADC being developed for the treatment of hematologic malignancies and solid tumors. Mersana's ADCs are designed to address unmet needs in oncology and target specific tumor antigens, allowing for more precise and effective therapies.
Mersana has also established collaborations with other pharmaceutical companies to further advance its ADC technology. They have partnered with Takeda Pharmaceutical Company Limited to develop an ADC utilizing Mersana's Fleximer platform. This collaboration aims to combine Takeda's expertise in oncology with Mersana's innovative drug delivery system.
Overall, Mersana Therapeutics Inc. is an innovative biopharmaceutical company dedicated to developing and commercializing novel ADC therapies to improve the lives of patients with cancer. Their cutting-edge technology, extensive pipeline, and strategic collaborations position them as a leader in the field of targeted cancer therapies.
Mersana's primary aim is to revolutionize cancer treatment by combining the specificity of antibodies with the potency of small molecules. By targeting cancer cells with precise antibodies and delivering potent drugs directly to them, Mersana's ADCs have the potential to enhance the efficacy of cancer therapies while minimizing the side effects associated with traditional treatments.
The company's proprietary platform, called Fleximer, forms the foundation of their ADC technology. Fleximer is a biodegradable polymer that can be customized to carry both small molecule drugs and antibodies. This platform enables the development of ADCs with enhanced stability, increased drug loading capacity, prolonged circulation time, and controlled drug release.
Mersana's lead product candidate, XMT-1536, is an ADC targeting NaPi2b, a protein highly expressed in multiple tumor types, including ovarian, lung, and colorectal cancers. XMT-1536 utilizes Fleximer to deliver a highly potent DNA crosslinking agent directly to cancer cells, leading to DNA damage and cell death. The company has completed Phase 1 clinical trials for XMT-1536 and is currently evaluating its safety and efficacy in various Phase 2 trials.
In addition to XMT-1536, Mersana has a pipeline of other ADC candidates at different stages of development. This includes XMT-1592, a CD205-targeted ADC being developed for the treatment of hematologic malignancies and solid tumors. Mersana's ADCs are designed to address unmet needs in oncology and target specific tumor antigens, allowing for more precise and effective therapies.
Mersana has also established collaborations with other pharmaceutical companies to further advance its ADC technology. They have partnered with Takeda Pharmaceutical Company Limited to develop an ADC utilizing Mersana's Fleximer platform. This collaboration aims to combine Takeda's expertise in oncology with Mersana's innovative drug delivery system.
Overall, Mersana Therapeutics Inc. is an innovative biopharmaceutical company dedicated to developing and commercializing novel ADC therapies to improve the lives of patients with cancer. Their cutting-edge technology, extensive pipeline, and strategic collaborations position them as a leader in the field of targeted cancer therapies.
Mersana Therapeutics, Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative antibody-drug conjugates (ADCs) for the treatment of cancer. ADCs are a class of targeted cancer therapies that combine an antibody, which can specifically recognize and bind to cancer cells, with a cytotoxic drug that kills those cells. Mersanas technology aims to enhance the effectiveness and reduce the side effects of traditional cancer treatments.
Segments
1. Oncology:
Mersana operates primarily within the oncology segment, focusing on various types of cancer. The company aims to address the limitations of existing chemotherapy and targeted therapies through its proprietary drug conjugate platforms.
2. Research and Development:
Mersana invests significantly in R&D, working on the design, synthesis, and preclinical development of its ADCs. This segment includes discovering new drug candidates, conducting preclinical studies, and initiating clinical trials.
Products
1. XMT-1536:
XMT-1536 is a proprietary ADC that targets the NaPi2b protein, which is overexpressed in various solid tumors, including ovarian cancer and non-small cell lung cancer (NSCLC). The product is designed to deliver a potent payload to cancer cells, thereby promoting targeted destruction while minimizing damage to surrounding healthy tissues. XMT-1536 has been evaluated in clinical trials, showing promise as a treatment option for patients with NaPi2b-expressing cancers.
2. XMT-1592:
XMT-1592 is another ADC in Mersanas pipeline that targets the same NaPi2b protein but utilizes a different payload or mechanism. This product is aimed at improving therapeutic efficacy and safety profiles, providing options for patients who may not respond to traditional therapies.
3. XMT-2056:
This is a novel ADC designed to target the HER2 and HER3 biomarkers, particularly in solid tumors that overexpress these proteins. HER2 is a well-known target in breast cancer therapy, and Mersanas ADC aims to enhance the targeting of cancer cells while reducing off-target effects seen with conventional treatments.
4. Next-Generation ADCs:
Mersana continues to innovate within the ADC space, exploring new linker technologies and payloads that can further improve its offerings. The company’s focus on improving the pharmacokinetics and tissue distribution of its products aims to enhance therapeutic windows and patient outcomes.
Services
1. Preclinical Development Services:
Mersana offers expertise in preclinical drug development, including formulation, pharmacology, and toxicology studies. This service is crucial for preparing candidates for clinical evaluation.
2. Partnerships and Collaborations:
The company often engages in strategic partnerships with other biopharmaceutical firms, research institutions, and academic organizations. These collaborations can facilitate resource sharing, expand research capabilities, and accelerate the development of new therapeutic candidates.
3. Clinical Trial Management:
Mersana manages and oversees clinical trials to test the safety and efficacy of its products. This involves designing trial protocols, recruiting participants, managing data collection and analysis, and ensuring compliance with regulatory requirements.
4. Regulatory Support:
Given the complexities of bringing new drugs to market, Mersana provides regulatory support throughout the drug development process. This includes preparing documentation for regulatory submissions and interacting with health authorities.
5. Commercialization Strategy Consulting:
Although still largely in the clinical development phase, Mersana may offer services related to commercialization strategies for their products, including market analysis, strategic pricing, and marketing plans aimed at oncologists and healthcare providers.
Through its focused approach on developing innovative cancer therapies using ADC technology, Mersana Therapeutics is positioned to contribute significantly to the oncology therapeutics landscape. The companys pipeline of ADC candidates reflects a commitment to enhancing targeted cancer treatments, paving the way for potential breakthroughs in patient care.
Segments
1. Oncology:
Mersana operates primarily within the oncology segment, focusing on various types of cancer. The company aims to address the limitations of existing chemotherapy and targeted therapies through its proprietary drug conjugate platforms.
2. Research and Development:
Mersana invests significantly in R&D, working on the design, synthesis, and preclinical development of its ADCs. This segment includes discovering new drug candidates, conducting preclinical studies, and initiating clinical trials.
Products
1. XMT-1536:
XMT-1536 is a proprietary ADC that targets the NaPi2b protein, which is overexpressed in various solid tumors, including ovarian cancer and non-small cell lung cancer (NSCLC). The product is designed to deliver a potent payload to cancer cells, thereby promoting targeted destruction while minimizing damage to surrounding healthy tissues. XMT-1536 has been evaluated in clinical trials, showing promise as a treatment option for patients with NaPi2b-expressing cancers.
2. XMT-1592:
XMT-1592 is another ADC in Mersanas pipeline that targets the same NaPi2b protein but utilizes a different payload or mechanism. This product is aimed at improving therapeutic efficacy and safety profiles, providing options for patients who may not respond to traditional therapies.
3. XMT-2056:
This is a novel ADC designed to target the HER2 and HER3 biomarkers, particularly in solid tumors that overexpress these proteins. HER2 is a well-known target in breast cancer therapy, and Mersanas ADC aims to enhance the targeting of cancer cells while reducing off-target effects seen with conventional treatments.
4. Next-Generation ADCs:
Mersana continues to innovate within the ADC space, exploring new linker technologies and payloads that can further improve its offerings. The company’s focus on improving the pharmacokinetics and tissue distribution of its products aims to enhance therapeutic windows and patient outcomes.
Services
1. Preclinical Development Services:
Mersana offers expertise in preclinical drug development, including formulation, pharmacology, and toxicology studies. This service is crucial for preparing candidates for clinical evaluation.
2. Partnerships and Collaborations:
The company often engages in strategic partnerships with other biopharmaceutical firms, research institutions, and academic organizations. These collaborations can facilitate resource sharing, expand research capabilities, and accelerate the development of new therapeutic candidates.
3. Clinical Trial Management:
Mersana manages and oversees clinical trials to test the safety and efficacy of its products. This involves designing trial protocols, recruiting participants, managing data collection and analysis, and ensuring compliance with regulatory requirements.
4. Regulatory Support:
Given the complexities of bringing new drugs to market, Mersana provides regulatory support throughout the drug development process. This includes preparing documentation for regulatory submissions and interacting with health authorities.
5. Commercialization Strategy Consulting:
Although still largely in the clinical development phase, Mersana may offer services related to commercialization strategies for their products, including market analysis, strategic pricing, and marketing plans aimed at oncologists and healthcare providers.
Through its focused approach on developing innovative cancer therapies using ADC technology, Mersana Therapeutics is positioned to contribute significantly to the oncology therapeutics landscape. The companys pipeline of ADC candidates reflects a commitment to enhancing targeted cancer treatments, paving the way for potential breakthroughs in patient care.